558
Participants
Start Date
June 20, 2011
Primary Completion Date
August 11, 2013
Study Completion Date
September 4, 2013
CXA-201
CXA-201 IV infusion (1500mg q8) for 7 days
Levofloxacin
Levofloxacin IV infusion (750mg qd) for 7 days
San Diego
Wheat Ridge
Hialeah
Teaneck
Charleston
Belo Horizonte
Porto Alegre
Joinville
Campinas
Sao Jose de Rio Preto
Rio de Janeiro
São Paulo
Santiago de Cali
Armenia
Barranquilla
Bogotá
Kohtla-Järve
Tallinn
Tartu
Tbilisi
Giessen
Lübeck
Miskolc
Gyor
Szentes
Sopron
Salgótarján
Nyíregyháza
Zalaegerszeg
Budapest
Tatabánya
Kfar Saba
Petah Tikva
Tel Litwinsky
Haifa
Jerusalem
Safed
Daugavpils
Liepāja
Riga
Valmiera
Ventspills
Guadalajara
Chihuahua City
San Luis Potosí City
Veracruz
Chisinau
Oradea
Bucharest
Timișoara
Brasov
Bucharest
Iași
Sibiu
Kemerovo
Moscow
Nizhny Novgorod
Novosibirsk
Penza
Saint Petersburg
Saratov
Belgrade
Banská Bystrica
Levice
Martin
Prešov
Skalica
Bloemfontein
Pretoria
Soweto
Middleburg
Bellville
Nakorn Ratchasima
Chiang Mai
Lopburi
Prachuap Khiri Khan
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
INDUSTRY